A post-hoc analysis to understand factors leading to initiation of a new rozanolixizumab cycle in the Phase 3 MycarinG and open-label extension (OLE) studies.
No takes yet. Share an insight, caveat, or question.
Mahuwala et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: